Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
NVO Novo Nordisk A/S
At-home administration devices (auto-injector devices) for GLP-1 therapies are part of Novo Nordisk’s delivery platform.
$226.67B
$50.27
+2.27%
BDX Becton, Dickinson and Company
BD develops auto‑injector devices (wearable injectors) for home/at‑home administration of biologics.
$55.06B
$192.05
+1.60%
TAK Takeda Pharmaceutical Company Limited
ENTYVIO Pen demonstrates the use of auto-injector devices for at-home administration of biologics.
$44.67B
$14.07
+0.43%
WST West Pharmaceutical Services, Inc.
Auto-Injector Devices are a key product category in West's GLP-1 and other injectable platforms.
$19.69B
$273.73
-1.25%
ROIV Roivant Sciences Ltd.
Auto-injector devices enabling at-home administration for IMVT-1402, fitting Auto-Injector Devices.
$14.56B
$21.32
+1.99%
HALO Halozyme Therapeutics, Inc.
Halozyme is expanding its portfolio of auto-injector devices to enable at-home/self-administration of therapies.
$8.26B
$70.63
+0.71%
ATR AptarGroup, Inc.
Aptar has auto-injector devices/platforms for at-home administration of injectable therapies.
$7.78B
$118.02
-0.21%
STVN Stevanato Group S.p.A.
Develops and manufactures Auto-Injector Devices for at-home/self-administration of injectable therapies.
$7.17B
$23.90
-1.12%
AMRX Amneal Pharmaceuticals, Inc.
DHE autoinjector (Brekiya) approval signals involvement in auto-injector device delivery systems.
$3.74B
$11.91
-0.33%
KE Kimball Electronics, Inc.
Auto-injector devices represent a differentiated medical device assembly capability.
$713.24M
$29.46
+5.55%
SCPH scPharmaceuticals Inc.
Auto-Injector Devices reflect the SCP-111 autoinjector program for at-home administration.
$299.33M
$5.67
ASRT Assertio Holdings, Inc.
Otrexup is an auto-injector device, fitting the Auto-Injector Devices category.
$83.23M
$0.87
-5.38%

Loading company comparison...

Loading research report...

BDX Becton, Dickinson and Company

BD Introduces Portable PureWick Collection System for Wheelchair Users and Mobility‑Restricted Patients

Nov 12, 2025
NVO Novo Nordisk A/S

Novo Nordisk Partners with Emcure to Distribute Poviztra in India

Nov 11, 2025
NVO Novo Nordisk A/S

Novo Nordisk Declines to Increase Offer for Metsera, Matching Pfizer’s Final Bid

Nov 09, 2025
HALO Halozyme Therapeutics, Inc.

FDA Approves DARZALEX Faspro® with Halozyme’s ENHANZE® Technology for High‑Risk Smoldering Multiple Myeloma

Nov 07, 2025
NVO Novo Nordisk A/S

Novo Nordisk’s CagriSema Shows Strong Blood‑Pressure, Inflammation, and Weight‑Loss Benefits in REDEFINE 1 Trial

Nov 07, 2025
TAK Takeda Pharmaceutical Company Limited

Takeda Reports Positive 18‑Month Interim Data for Mezagitamab in IgA Nephropathy

Nov 07, 2025
BDX Becton, Dickinson and Company

Becton, Dickinson Reports Q4 2025 Earnings: Adjusted EPS Beats Estimates, Revenue Slightly Misses Forecasts

Nov 06, 2025
NVO Novo Nordisk A/S

Trump Administration, Novo Nordisk, and Eli Lilly Announce Pricing Deal to Reduce GLP‑1 Obesity Drug Costs and Expand Medicare Coverage

Nov 06, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Posts Q3 2025 Earnings Beat, Highlights Strong High‑Value Solutions Growth

Nov 06, 2025
NVO Novo Nordisk A/S

Novo Nordisk Reports Q3 2025 Earnings: Revenue Misses Guidance Amid Slowing GLP‑1 Demand

Nov 05, 2025
BDX Becton, Dickinson and Company

BD Reaches Full Enrollment of Iliac Artery Cohort in AGILITY Study for Revello Vascular Stent

Nov 04, 2025
BDX Becton, Dickinson and Company

BD Receives FDA 510(k) Clearance and CE‑IVDR Certification for New High‑Throughput Enteric Bacterial Panels

Nov 03, 2025
NVO Novo Nordisk A/S

Pfizer Files Second Lawsuit Against Novo Nordisk Over Metsera Acquisition

Nov 03, 2025
TAK Takeda Pharmaceutical Company Limited

Takeda Completes 7‑Year Phase 3 Trial of Dengue Vaccine QDENGA, Delivering Long‑Term Efficacy Data

Nov 03, 2025
NVO Novo Nordisk A/S

Pfizer Sues Novo Nordisk Over Metsera Acquisition Bid, Citing Interference with Existing Deal

Nov 01, 2025
ATR AptarGroup, Inc.

AptarGroup Reports Q3 2025 Earnings: Net Income $127.9 Million, EPS $1.92

Oct 31, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Reports Third‑Quarter 2025 Financial Results, Raises 2025 Guidance for Adjusted EBITDA and EPS

Oct 30, 2025
TAK Takeda Pharmaceutical Company Limited

Takeda Reports First‑Half FY2025 Results, Revises Full‑Year Outlook, and Highlights Pipeline Progress

Oct 30, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Launches Brekiya® – First and Only DHE Autoinjector for Migraine and Cluster Headaches

Oct 27, 2025
BDX Becton, Dickinson and Company

BD Simplifies At‑Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States

Oct 23, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Reports Third‑Quarter 2025 Results

Oct 23, 2025
TAK Takeda Pharmaceutical Company Limited

Takeda Announces $11.4 Billion Strategic Partnership with Innovent Biologics to Advance Oncology Pipeline

Oct 22, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Expands Drug Delivery Capacity in Germany

Oct 21, 2025
ATR AptarGroup, Inc.

Aptar Digital Health Receives FDA 510(k) Clearance for HeroTracker® Sense

Oct 16, 2025
BDX Becton, Dickinson and Company

Becton Dickinson Announces CFO Transition, Names Interim CFO

Oct 15, 2025
NVO Novo Nordisk A/S

Novo Nordisk to Close Cell Therapy Division Amid Global Restructuring

Oct 10, 2025
NVO Novo Nordisk A/S

Novo Nordisk to Acquire Akero Therapeutics for up to $5.2 Billion, Expanding into Liver Disease Treatments

Oct 09, 2025
NVO Novo Nordisk A/S

Novo Nordisk Announces 9,000 Job Cuts and Revised Profit Outlook in Major Restructuring

Sep 10, 2025
NVO Novo Nordisk A/S

Wegovy Shows Superior Cardiovascular Benefits Over Eli Lilly's Tirzepatide in Real-World Study

Sep 01, 2025
NVO Novo Nordisk A/S

FDA Approves First-Ever Generic Weight-Loss Drug, a Saxenda Copycat

Aug 28, 2025
NVO Novo Nordisk A/S

FDA Approves Wegovy for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Aug 21, 2025
NVO Novo Nordisk A/S

Novo Nordisk Implements Global Hiring Freeze Amid Cost-Cutting Push

Aug 20, 2025
NVO Novo Nordisk A/S

Novo Nordisk Trims Outlook Amid Rising Rivalry in Q2 2025 Earnings

Aug 06, 2025
NVO Novo Nordisk A/S

NVIDIA Announces Collaboration with Novo Nordisk to Advance AI Drug Discovery

Jul 13, 2025
NVO Novo Nordisk A/S

Italian Authorities Boost Novo Nordisk's Proposed $2.34 Billion Factory Investment

Jul 09, 2025
NVO Novo Nordisk A/S

Novo Nordisk Launches Wegovy in India Amid Surging Demand for Obesity Drugs

Jul 07, 2025
NVO Novo Nordisk A/S

Report: Novo Nordisk Executives Ignored Internal Warnings on Wegovy Launch Preparedness

Jul 01, 2025
NVO Novo Nordisk A/S

Novo Nordisk Partners with WeightWatchers to Expand Wegovy Access at $299 Price

Jun 26, 2025
NVO Novo Nordisk A/S

Novo Nordisk Terminates Partnership with Hims & Hers Health Over Compounded Drug Sales

Jun 23, 2025
NVO Novo Nordisk A/S

Mim8 Prophylaxis Treatment Shows Good Tolerability in Hemophilia A Phase III Data

Jun 22, 2025
NVO Novo Nordisk A/S

Novo Nordisk Loses Canadian Patent Protection on Blockbuster Drug

Jun 17, 2025
NVO Novo Nordisk A/S

Novo Nordisk Advances Amycretin to Phase III Clinical Development

Jun 12, 2025
NVO Novo Nordisk A/S

Novo Nordisk Forms AI and Drug Discovery Alliances with Nvidia and Deep Apple

Jun 11, 2025
NVO Novo Nordisk A/S

Novo Nordisk Stock Climbs on Report of Activist Investor Parvus Building Stake

Jun 10, 2025
NVO Novo Nordisk A/S

European Regulators Link Wegovy to Rare Vision-Loss Disorder

Jun 06, 2025
NVO Novo Nordisk A/S

Evernorth Deals Cap Wegovy Copays at $200, Expanding Access

May 22, 2025
NVO Novo Nordisk A/S

Novo Nordisk Announces CEO Transition: Lars Fruergaard Jørgensenm Resigns, Mike Doustdar Appointed

May 16, 2025
NVO Novo Nordisk A/S

US FDA Accepts Novo Nordisk's Application for Oral Wegovy

May 02, 2025
NVO Novo Nordisk A/S

FDA Alerts to Counterfeit Ozempic in US Supply Chain with Fake Labels and Needles

Apr 15, 2025
NVO Novo Nordisk A/S

Novo Nordisk's Head of Commercial Strategy Steps Down

Apr 03, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks